Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC9733-0001 · 1 trial · 2 indications
Measured as number of events
Measured as number of episodes
| Arm | Type | Description |
|---|---|---|
| NNC9733-0001 | EXPERIMENTAL | Participants will be administered a single dose of NNC9733-0001 in a dose escalated manner. |
| Placebo | EXPERIMENTAL | Participants will be administered a single dose of matching NNC9733-0001 placebo in a dose escalated manner. |
| Name | Type | Description |
|---|---|---|
| NNC9733-0001 | DRUG | Administered a single dose of NNC9733-0001. |
| Placebo | DRUG | Administered a single dose of matching NNC9733-0001 placebo. |
Inclusion Criteria: All participants * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study. * Male, or female of nonchildbearing potential ...
NNC9733-0001 is an investigational small molecule being developed by Novo Nordisk for metabolic conditions. It is currently in a Phase 1 clinical trial in healthy volunteers and participants with type 2 diabetes. The drug is not approved and remains in clinical development.
NNC9733-0001 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting a Phase 1 trial of this investigational small molecule in Germany.
NNC9733-0001 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing trial is recruiting participants to evaluate the new medicine in healthy volunteers and those with type 2 diabetes.
NNC9733-0001 is being studied in one active Phase 1 trial, identified as NCT07270731. This randomized, double-blind, controlled study is recruiting 60 participants in Germany, including healthy volunteers and individuals with type 2 diabetes, with a minimum age of 18 years.
NNC9733-0001 is the only name provided for this investigational drug. No alternative names have been reported for this small molecule being developed by Novo Nordisk for metabolic conditions.